Literature DB >> 9018234

Antitumor effect of locally produced CD95 ligand.

K Seino1, N Kayagaki, K Okumura, H Yagita.   

Abstract

Activation of the cell-surface antigen CD95 induces apoptosis of CD95-bearing tumor cells. In this study, we investigated the antitumor effect of locally produced CD95 ligand (CD95L) on CD95-negative tumor cells in vivo. Introduction of CD95L cDNA into murine tumor cells did not affect growth in vitro but caused rejection in vivo. Neutrophils were primarily responsible for this rejection. A CD8 T cell-mediated protective immunity against subsequent challenge with parental tumor cells was also elicited. These results provide evidence for the potential utility of CD95L in tumor eradication and also reveal a proinflammatory function of CD95L.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9018234     DOI: 10.1038/nm0297-165

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  53 in total

1.  Inhibition of mitogen-activated kinase signaling sensitizes HeLa cells to Fas receptor-mediated apoptosis.

Authors:  T H Holmström; S E Tran; V L Johnson; N G Ahn; S C Chow; J E Eriksson
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

2.  CD95 and CD95L promote and protect cancer stem cells.

Authors:  Paolo Ceppi; Abbas Hadji; Frederick J Kohlhapp; Abhinandan Pattanayak; Annika Hau; Xia Liu; Huiping Liu; Andrea E Murmann; Marcus E Peter
Journal:  Nat Commun       Date:  2014-11-04       Impact factor: 14.919

3.  CD95 ligand expression as a mechanism of immune escape in breast cancer.

Authors:  M Müschen; C Moers; U Warskulat; J Even; D Niederacher; M W Beckmann
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

Review 4.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

5.  Novel role of regulatory T cells in limiting early neutrophil responses in skin.

Authors:  Hannah Richards; Anwen Williams; Emma Jones; James Hindley; Andrew Godkin; Anna Katharina Simon; Awen Gallimore
Journal:  Immunology       Date:  2010-08-17       Impact factor: 7.397

6.  Mesenchymal stromal cells inhibit murine syngeneic anti-tumor immune responses by attenuating inflammation and reorganizing the tumor microenvironment.

Authors:  Jaime F Modiano; Beth A Lindborg; Ron T McElmurry; Mitzi Lewellen; Colleen L Forster; Edward A Zamora; Jerome Schaack; Donald Bellgrau; Timothy D O'Brien; Jakub Tolar
Journal:  Cancer Immunol Immunother       Date:  2015-08-07       Impact factor: 6.968

7.  Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer.

Authors:  H Zhang; Y Yang; J L Horton; E B Samoilova; T A Judge; L A Turka; J M Wilson; Y Chen
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

Review 8.  Fas (CD95, Apo-1) ligand gene transfer.

Authors:  S E Lamhamedi-Cherradi; Y Chen
Journal:  J Clin Immunol       Date:  2001-01       Impact factor: 8.317

9.  Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.

Authors:  M W Bennett; J O'connell; G C O'sullivan; D Roche; C Brady; J Kelly; J K Collins; F Shanahan
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

10.  Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth.

Authors:  Céline A Blache; Edwin R Manuel; Teodora I Kaltcheva; Andrea N Wong; Joshua D I Ellenhorn; Bruce R Blazar; Don J Diamond
Journal:  Cancer Res       Date:  2012-10-22       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.